Physician profile
Ronald M Eimen
NPI 1588756951
$5,610.03
in general payments reported to CMS, 2019-2025
33 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $858 · 2021: $1,200 · 2022: $551 · 2023: $675 · 2024: $1,115 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,570.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,367.44 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $847.70 | 2019-2022 | |
| Lilly USA, LLC | $571.38 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $477.50 | 2021-2025 | |
| Glaxosmithkline, LLC. | $456.00 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $272.56 | 2019-2024 | Ozempic |
| Astellas Pharma US INC | $257.50 | 2019-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $234.28 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.20 | 2019-2024 | Jardiance |
| Alk-Abello, INC | $166.32 | 2024 | Grastek, Ragwitek, Odactra |
| Sumitomo Pharma America, INC. | $84.52 | 2023-2024 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $76.06 | 2025 | Austedo Xr |
| Lundbeck LLC | $66.39 | 2024-2025 | Rexulti |
| Horizon Therapeutics Plc | $55.15 | 2021-2022 | |
| Pfizer INC. | $51.36 | 2019-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $38.82 | 2025 | Fanapt |
| Dexcom, INC. | $37.98 | 2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $37.45 | 2020 | |
| Exact Sciences Corporation | $30.86 | 2023 | Cologuard Collection Kit |
| Insulet Corporation | $30.19 | 2023 | Omnipod |
| Mylan Specialty L.P. | $22.90 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $22.49 | 2024 | Rexulti |
| Hologic Sales and Service, LLC | $21.52 | 2020 | |
| Pharmacosmos Therapeutics INC. | $16.90 | 2023 | Monoferric |
| Abiomed | $16.86 | 2024 | Impella |
| Novartis Pharmaceuticals Corporation | $16.12 | 2020 | |
| Jazz Pharmaceuticals INC. | $16.10 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.84 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.18 | 2020 | |
| Xeris Pharmaceuticals, INC. | $14.46 | 2024 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $14.32 | 2024 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $14.21 | 2023 | Eliquis |
| Alfasigma USA, INC. | $13.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Eimen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.